AnteoTech Ltd (AU:ADO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AnteoTech Ltd is witnessing an expansion in its collaboration with the Serum Institute of India, as the institute plans to increase its usage of AnteoBind technology, leading to expected additional orders. Simultaneously, AnteoTech is progressing towards a commercial agreement with Vidcare Innovations for the use of AnteoBind NXT in diagnostic tests, targeting a launch in 2025. These developments position AnteoTech to capitalize on the booming Indian healthcare market, which is projected to exceed $638 billion by 2025.
For further insights into AU:ADO stock, check out TipRanks’ Stock Analysis page.